Skip to main content

Table 1 The association between FTO expression and clinical characteristics

From: m6A eraser FTO impairs gemcitabine resistance in pancreatic cancer through influencing NEDD4 mRNA stability by regulating the PTEN/PI3K/AKT pathway

Variable

Group

FTO expression

P value

Low (%)

High (%)

Gender

   

0.848

Male

19 (48.7)

20 (51.3)

 

Female

5 (45.5)

6 (54.5)

 

Age (year)

   

0.701

 < 60

5 (38.5)

8 (61.5)

 

 ≥ 63

20 (44.4)

25 (55.6)

 

T

   

0.024*

T1 or T2

22 (59.5)

15 (40.5)

 

T3 or T4

3 (23.1)

10 (76.9)

 

N

   

0.765

0

8 (47.1)

9 (52.9)

 

1 or 2

17 (51.5)

16 (48.5)

 

M

   

0.552

0

24 (51.1)

23 (48.9)

 

1

1 (33.3)

2 (66.7)

 

Stage

   

0.382

IA-IIB

14 (45.2)

17 (54.8)

 

III-IV

11 (57.9)

8 (42.1)

 

Tumor size

   

0.020*

 ≤ 3 cm

20 (69.0)

9 (31.0)

 

 > 3.5 cm

5 (23.8)

16 (76.2)

Â